2018
DOI: 10.1096/fasebj.2018.32.1_supplement.531.17
|View full text |Cite
|
Sign up to set email alerts
|

Screening of in silico identified inhibitors of breast cancer resistance protein (BCRP) transporter in BCRP‐overexpressing MCF‐7 M100 cancer cells

Abstract: The overexpression of breast cancer resistance protein (BCRP) is associated with multidrug resistance (MDR) in specific cancers. BCRP is an ATP‐binding cassette (ABC) transporter that is also functionally important in the blood brain barrier. The ability of BCRP to export cancer chemotherapeutics to sub‐therapeutic concentrations renders chemotherapy treatment ineffective in cancers that overexpress BCRP. BCRP can also be problematic in its ability to inhibit the delivery of drugs to the brain. There are curre… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles